LitAlert ~~ GeneLit.com

    • The Effect of Age on Outcomes After Neoadjuvant Chemotherapy for Breast Cancer.
    • Verdial FC, Mamtani A, Pawloski KR, Sevilimedu V, D'Alfonso TM, Zhang H, Gemignani ML, Barrio AV, Morrow M, Tadros AB.
    • Ann Surg Oncol. 2022 Mar 5. doi: 10.1245/s10434-022-11367-w. Epub ahead of print.
    • Li-Fraumeni syndrome in Tunisian carriers with different and rare tumor phenotype: genotype-phenotype correlation.
    • Sassi H, Meddeb R, Cherif MA, Nasr C, Riahi A, Hannachi S, Belguith N, M'rad R.
    • BMC Med Genomics. 2022 Mar 4;15(1):44. doi: 10.1186/s12920-022-01189-w.
    • Toward a better understanding of the experience of patients with moderate penetrance breast cancer gene pathogenic/likely pathogenic variants: A focus on ATM and CHEK2.
    • McCormick S, Hicks S, Wooters M, Grant C.
    • J Genet Couns. 2022 Mar 4. doi: 10.1002/jgc4.1568. Epub ahead of print.
    • The role of genetic testing in prostate cancer screening, diagnosis, and treatment.
    • de la Calle CM, Bhanji Y, Pavlovich CP, Isaacs WB.
    • Curr Opin Oncol. 2022 Mar 2. doi: 10.1097/CCO.0000000000000823. Epub ahead of print.
    • Review
    • Next step in molecular genetics of hereditary breast/ovarian cancer: Multigene panel testing in clinical actionably genes and prioritization algorithms in the study of variants of uncertain significance.
    • Castillo-Guardiola V, Rosado-Jiménez L, Sarabia-Meseguer M, Marín-Vera M, Macías-Cerrolaza JA, García-Hernández R, Zafra-Poves M, Sánchez-Henarejos P, Moreno-Locubiche MÁ, Cuevas-Tortosa E, Arnaldos-Carrillo M, Ayala-de-la-Peña F, Alonso-Romero JL, Noguera-Velasco JA, Ruiz-Espejo F.
    • Eur J Med Genet. 2022 Mar 1:104468. doi: 10.1016/j.ejmg.2022.104468. Epub ahead of print.
    • BRCA testing and testing results among women 18-65 years old.
    • Guo F, Scholl M, Fuchs EL, Berenson AB, Kuo YF.
    • Prev Med Rep. 2022 Feb 19;26:101738. doi: 10.1016/j.pmedr.2022.101738.